SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease

Journal of Neuroimaging

Volumn 23, Issue 2, 2013, Pages 192-196

  Hwang, Wen Juh ^a   Yao, Wei Jen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Dopa mine transporter; Dopamine D2 receptor; Huntington's disease; Single photon emission computed tomography

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; IOLOPRIDE I 123;

ADULT; ARTICLE; BINDING KINETICS; CASE REPORT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HUMAN; HUNTINGTON CHOREA; MALE; NIGRONEOSTRIATAL SYSTEM; OCCIPITAL LOBE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BENZAMIDES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEURAL PATHWAYS; ORGANOTECHNETIUM COMPOUNDS; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84876315034     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2011.00671.x     Document Type: Article

References (28)

1. Goto S, Hirano A, Rojas-Corona RR. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 1989;25:298-304.
2. Cross A, Rossor M. Dopamine D-1 and D-2 receptors in Huntington's disease. Eur J Pharmacol 1983;88:223-229.
3. Andrews TC, Weeks RA, Turjanski N, et al. Huntington's disease progression: PET and clinical observations. Brain 1999;122:2353-2363.
4. Joyce JN, Lexow N, Bird E, et al. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988;2:546-557.
5. Reisine TD, Fields JZ, Stern LZ, et al. Alterations in dopaminergic receptors in Huntington's disease. Life Sci 1977;21:1123-1128.
6. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120:503-514.
7. Turjanski N, Weeks R, Dolan R, et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995;118:689-696.
8. Brandt J, Folstein SE, Wong DF, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. Neuropsychiatry Clin Neurosci 1990;2:20-27.
9. Leenders KL, Frackowiak RS, Quinn N, et al. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord 1986;1:69-77.
10. Pavese N, Andrews TC, Brooks DJ, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003;126:1127-1135.
11. Bäckman L, Robins-Wahlin TB, Lundin A, et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997;120:2207-2217.
12. Sedvall G, Karlsson P, Lundin A, et al. Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994;243:249-255.
13. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119:2085-2095.
14. Brucke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220-228.
15. Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 1997;38:1711-1717.
16. 123I-IBZM in humans. Ann Nucl Med 1993;7:29-38.
17. Staffen W, Hondl N, Trinka E, et al. SPET investigations in extrapyramidal diseases using specific ligands. Nucl Med Commun 1997;18:159-163.
18. Leslie WD, Greenberg CR, Abrams DN, et al. Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography. Eur J Nucl Med 1999;26:1458-1464.
19. Van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005;65:941-943.
20. Bohnen NI, Koeppe RA, Meyer P, et al. Decreased striatal monoaminergic terminals in Huntington's disease. Neurology 2000;54:1753-1759.
21. Goldberg YP, Andrew SE, Theilmann J, et al. Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. J Med Genet 1993;30:987-990.
22. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
23. 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med 2004;45:207-213.
24. Hwang WJ, Yao WJ, Wey SP, et al. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. Eur Neurol 2002;47:113-117.
25. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;NS25;638-643.
26. Camps M, Cortés R, Gueye B, et al. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989;28:275-290.
27. Kung HF, Kim HJ, Kung MP, et al. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996;23:1527-1530.
28. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401-1406.